https://www.selleckchem.com/products/ly364947.html
8, and local recurrence (OR 4.35, 95% CI 2.00-9.44). Complete remission in the metastatic setting was observed in five patients, most of whom were treated with multimodal therapy. Median survival in patients with metastatic disease was 18months (IQR 7-43). Malignant MTVT is a rare but aggressive disease. Since local recurrence is a risk factor for metastatic progression, we recommend aggressive local treatment. Survival and response to any treatment in the metastatic setting are limited. Malignant MTVT is a rare but aggressive diseas
Aimer
Commentaire
Partagez
